



03 October 2023

**cyclo**medica  
**techneg**as

Cyclopharm Ltd  
ABN 74 116 931 250  
Unit 4, 1 The Crescent  
Kingsgrove NSW 2208 Australia  
T 61 2 9541 0411  
F 61 2 9543 0960  
www.cyclopharm.com.au

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

## USFDA TECHNEGAS® APPROVAL WEBINAR

Cyclopharm (ASX:CYC), the health technology company that is a world leader in functional lung ventilation imaging through its proprietary product Technegas®, will be hosting a webinar for shareholders and investors on **Thursday, 05 October 2023** to discuss its recent United States Food and Drug Administration (USFDA) approval.

Cyclopharm's Managing Director, James McBrayer, will provide an update on the initial US\$180 million opportunity in the diagnosis and management of Pulmonary Embolism (PE) created by the USFDA approving Cyclopharm's proprietary Technegas™ technology for sale in the US market and the exponentially larger opportunity of *Beyond PE* applications.

The webinar will commence at **2 pm (AEST)] on Thursday, 05 October 2023**. All shareholders and investors are welcome to attend, with registration via the address below:

**[https://cyclopharm-au.zoom.us/webinar/register/WN\\_O9FZzUFoSHuOz1cLQIxsMA](https://cyclopharm-au.zoom.us/webinar/register/WN_O9FZzUFoSHuOz1cLQIxsMA)**

Once registered, participants will be provided with full details of the link to the webinar.

ENDS

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

**For more information, please contact:**

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411

### **Cyclopharm Limited**

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

**Technegas**

The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.